Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Antibiotics Market: By Drug Class, By Action Mechanism, By Spectrum, and Geography
Antibiotics Market: By Drug Class, By Action Mechanism, By Spectrum, and Geography
| 1. Executive Summary |
| 2. Global Antibiotics Market Introduction |
| 2.1. Global Antibiotics Market – Taxonomy |
| 2.2. Global Antibiotics Market –Definitions |
| 2.2.1. By Drug Class |
| 2.2.2. By Action Mechanism |
| 2.2.3. By Spectrum |
| 2.2.4. By Region |
| 3. Global Antibiotics Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Global Antibiotics Market Dynamic Factors - Impact Analysis |
| 3.6. Global Antibiotics Market – Competition Landscape |
| 4. Global Antibiotics Market Analysis,2019 - 2023 and Forecast, 2024 - 2030 |
| 4.1. Market Analysis,2019 - 2023 and Forecast, 2024 - 2030 (Revenue, US$ Mn) |
| 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Antibiotics Market, By Drug Class, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, US$ Mn) |
| 5.1. Cephalosporins |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, US$ Mn) |
| 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Penicillins |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, US$ Mn) |
| 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Fluroquinilones |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, US$ Mn) |
| 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Macrolides |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, US$ Mn) |
| 5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Carbapenems |
| 5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, US$ Mn) |
| 5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. Aminoglycosides |
| 5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, US$ Mn) |
| 5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 5.7. Sulfonamides |
| 5.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, US$ Mn) |
| 5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| Market Opportunity Analysis |
| 5.8. Others |
| 5.8.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, US$ Mn) |
| 5.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.8.3. Market Opportunity Analysis |
| 6. Global Antibiotics Market Forecast, By Action Mechanism, 2019 - 2023 and Forecast, 2021 – 2027 (Revenue, US$ Mn) |
| 6.1. Cell Wall Synthesis Inhibitors |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, US$ Mn) |
| 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Protein Synthesis Inhibitors |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, US$ Mn) |
| 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. DNA Synthesis Inhibitors |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, US$ Mn) |
| 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. RNA Synthesis Inhibitors |
| 6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, US$ Mn) |
| 6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Mycolic Acid Inhibitors |
| 6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, US$ Mn) |
| 6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 6.6. Others |
| 6.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, US$ Mn) |
| 6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.6.3. Market Opportunity Analysis |
| 7. Global Antibiotics Market, By Spectrum, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, US$ Mn) |
| 7.1. Broad-spectrum Antibiotics |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, US$ Mn) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Narrow-spectrum Antibiotics |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, US$ Mn) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 8. Global Antibiotics Market Forecast, By Region, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, US$ Mn) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, US$ Mn) |
| 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, US$ Mn) |
| 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia-Pacific |
| 8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, US$ Mn) |
| 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Latin America |
| 8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, US$ Mn) |
| 8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Middle East and Africa |
| 8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, US$ Mn) |
| 8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 8.6. Global Antibiotics Market - Opportunity Analysis Index, By Drug Class, Action Mechanism, Spectrum, and Region, 2024 - 2030 |
| 9. North America Antibiotics MarketAnalysis,2019 - 2023 and Forecast, 2024 - 2030 (Revenue, US$ Mn) |
| 9.1. By Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030by Revenue (US$ Mn),Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1. Cephalosporins |
| 9.1.2. Penicillins |
| 9.1.3. Fluroquinilones |
| 9.1.4. Macrolides |
| 9.1.5. Carbapenems |
| 9.1.6. Aminoglycosides |
| 9.1.7. Sulfonamides |
| 9.1.8. Others |
| 9.2. Action Mechanism Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (US$ Mn), Y-o-Y Growth (%) and Market Share (%) |
| 9.2.1. Cell Wall Synthesis Inhibitors |
| 9.2.2. Protein Synthesis Inhibitors |
| 9.2.3. DNA Synthesis Inhibitors |
| 9.2.4. RNA Synthesis Inhibitors |
| 9.2.5. Mycolic Acid Inhibitors |
| 9.2.6. Others |
| 9.3. Spectrum Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (US$ Mn), Y-o-Y Growth (%) and Market Share (%) |
| 9.3.1. Broad-spectrum Antibiotics |
| 9.3.2. Narrow-spectrum Antibiotics |
| 9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030by Revenue (US$ Mn) Y-o-Y Growth (%) and Market Share (%) |
| 9.4.1. USA |
| 9.4.2. Canada |
| 9.5. North America Antibiotics Market - Opportunity Analysis Index, By Drug Class, Action Mechanism, Spectrum, and Country, 2024 - 2030 |
| 9.6. North America Antibiotics Market Dynamics – Trends |
| 10. Europe Antibiotics Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, US$ Mn) |
| 10.1. By Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030by Revenue (US$ Mn),Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1. Cephalosporins |
| 10.1.2. Penicillins |
| 10.1.3. Fluroquinilones |
| 10.1.4. Macrolides |
| 10.1.5. Carbapenems |
| 10.1.6. Aminoglycosides |
| 10.1.7. Sulfonamides |
| 10.1.8. Others |
| 10.2. Action Mechanism Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (US$ Mn), Y-o-Y Growth (%) and Market Share (%) |
| 10.2.1. Cell Wall Synthesis Inhibitors |
| 10.2.2. Protein Synthesis Inhibitors |
| 10.2.3. DNA Synthesis Inhibitors |
| 10.2.4. RNA Synthesis Inhibitors |
| 10.2.5. Mycolic Acid Inhibitors |
| 10.2.6. Others |
| 10.3. Spectrum Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (US$ Mn), Y-o-Y Growth (%) and Market Share (%) |
| 10.3.1. Broad-spectrum Antibiotics |
| 10.3.2. Narrow-spectrum Antibiotics |
| 10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (US$ Mn) Y-o-Y Growth (%) and Market Share (%) |
| 10.4.1. Germany |
| 10.4.2. UK |
| 10.4.3. France |
| 10.4.4. Spain |
| 10.4.5. Italy |
| 10.4.6. Russia |
| 10.4.7. Poland |
| 10.4.8. Rest of Europe |
| 10.5. Europe Antibiotics Market - Opportunity Analysis Index, By Drug Class, Action Mechanism, Spectrum, and Country, 2024 - 2030 |
| 10.6. Europe Antibiotics Market Dynamics – Trends |
| 11. Asia-Pacific Antibiotics Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, US$ Mn) |
| 11.1. By Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030by Revenue (US$ Mn),Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1. Cephalosporins |
| 11.1.2. Penicillins |
| 11.1.3. Fluroquinilones |
| 11.1.4. Macrolides |
| 11.1.5. Carbapenems |
| 11.1.6. Aminoglycosides |
| 11.1.7. Sulfonamides |
| 11.1.8. Others |
| 11.2. Action Mechanism Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (US$ Mn), Y-o-Y Growth (%) and Market Share (%) |
| 11.2.1. Cell Wall Synthesis Inhibitors |
| 11.2.2. Protein Synthesis Inhibitors |
| 11.2.3. DNA Synthesis Inhibitors |
| 11.2.4. RNA Synthesis Inhibitors |
| 11.2.5. Mycolic Acid Inhibitors |
| 11.2.6. Others |
| 11.3. Spectrum Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (US$ Mn), Y-o-Y Growth (%) and Market Share (%) |
| 11.3.1. Broad-spectrum Antibiotics |
| 11.3.2. Narrow-spectrum Antibiotics |
| 11.4. Country Analysis2019 - 2023 and Forecast 2024 - 2030 by Revenue (US$ Mn) Y-o-Y Growth (%) and Market Share (%) |
| 11.4.1. Japan |
| 11.4.2. China |
| 11.4.3. India |
| 11.4.4. ASEAN |
| 11.4.5. Australia & New Zealand |
| 11.4.6. Rest of Asia-Pacific |
| 11.5. Asia-Pacific Antibiotics Market - Opportunity Analysis Index, By Drug Class, Action Mechanism, Spectrum, and Country, 2024 - 2030 |
| 11.6. Asia-Pacific Antibiotics Market Dynamics – Trends |
| 12. Latin America Antibiotics Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, US$ Mn) |
| 12.1. By Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030by Revenue (US$ Mn),Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1. Cephalosporins |
| 12.1.2. Penicillins |
| 12.1.3. Fluroquinilones |
| 12.1.4. Macrolides |
| 12.1.5. Carbapenems |
| 12.1.6. Aminoglycosides |
| 12.1.7. Sulfonamides |
| 12.1.8. Others |
| 12.2. Action Mechanism Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (US$ Mn), Y-o-Y Growth (%) and Market Share (%) |
| 12.2.1. Cell Wall Synthesis Inhibitors |
| 12.2.2. Protein Synthesis Inhibitors |
| 12.2.3. DNA Synthesis Inhibitors |
| 12.2.4. RNA Synthesis Inhibitors |
| 12.2.5. Mycolic Acid Inhibitors |
| 12.2.6. Others |
| 12.3. Spectrum Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (US$ Mn), Y-o-Y Growth (%) and Market Share (%) |
| 12.3.1. Broad-spectrum Antibiotics |
| 12.3.2. Narrow-spectrum Antibiotics |
| 12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (US$ Mn) Y-o-Y Growth (%) and Market Share (%) |
| 12.4.1. Brazil |
| 12.4.2. Mexico |
| 12.4.3. Argentina |
| 12.4.4. Rest of Latin America |
| 12.5. Latin America Antibiotics Market - Opportunity Analysis Index, By Drug Class, Action Mechanism, Spectrum, and Country, 2024 - 2030 |
| 12.6. Latin America Antibiotics Market Dynamics – Trends |
| 13. Middle East and Africa Antibiotics Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, US$ Mn) |
| 13.1. By Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030by Revenue (US$ Mn),Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1. Cephalosporins |
| 13.1.2. Penicillins |
| 13.1.3. Fluroquinilones |
| 13.1.4. Macrolides |
| 13.1.5. Carbapenems |
| 13.1.6. Aminoglycosides |
| 13.1.7. Sulfonamides |
| 13.1.8. Others |
| 13.2. Action Mechanism Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (US$ Mn), Y-o-Y Growth (%) and Market Share (%) |
| 13.2.1. Cell Wall Synthesis Inhibitors |
| 13.2.2. Protein Synthesis Inhibitors |
| 13.2.3. DNA Synthesis Inhibitors |
| 13.2.4. RNA Synthesis Inhibitors |
| 13.2.5. Mycolic Acid Inhibitors |
| 13.2.6. Others |
| 13.3. Spectrum Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (US$ Mn), Y-o-Y Growth (%) and Market Share (%) |
| 13.3.1. Broad-spectrum Antibiotics |
| 13.3.2. Narrow-spectrum Antibiotics |
| 13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (US$ Mn) Y-o-Y Growth (%) and Market Share (%) |
| 13.4.1. Gulf Cooperation Council (GCC) Countries |
| 13.4.2. Israel |
| 13.4.3. South Africa |
| 13.4.4. Rest of MEA |
| 13.5. MEA Antibiotics Market - Opportunity Analysis Index, By Drug Class, Action Mechanism, Spectrum, and Country, 2024 - 2030 |
| 13.6. MEA Antibiotics Market Dynamics – Trends |
| 14. Competition Landscape |
| 14.1. Strategic Dashboard of Top Market Players |
| 14.2. Company Profiles (Introduction, Financial Analysis, Action Mechanism& Service Offerings, Key Developments, Strategies, and SWOT Analysis) |
| 14.2.1. Abbott Laboratories |
| 14.2.2. Allergan Plc. |
| 14.2.3. F. Hoffmann-La Roche Ltd. |
| 14.2.4. GlaxoSmithKline plc |
| 14.2.5. Merck & Co. Inc. |
| 14.2.6. Mylan N.V. |
| 14.2.7. Novartis International AG (Sandoz) |
| 14.2.8. Pfizer Inc. |
| 14.2.9. Sanofi |
| 14.2.10. Teva Pharmaceutical Industries Ltd. |
| 15. Research Methodology |
| 16. Key Assumptions and Acronyms |
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
2023 is the base year and 2030 is the forecast year.
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.